CRT is able to provide access to the most exciting oncology related opportunities through its partnerships with prestigious international research institutes and funding bodies. In addition, CRT's Development Laboratory also plays a pivotal role in creating robust licensing opportunities. Where possible the company's strategy is to develop therapeutics up to and including in vivo efficacy studies.

Currently, CRT is associated with three marketed cancer related therapies and more than fifteen partnered therapeutics in clinical development . Through these activities, CRT is a self-financing organisation with gross revenues in excess of £25m per annum.